In light of previous results, a 6-molecule surface fingerprint containing EpCAM, CD9, CD44, CD59, CD95, and SSEA-4 was examined in the Pop1 and Pop3 PCa patient sample subpopulations to prove its potential as a comprehensive fingerprint for prediction of docetaxel resistance or sensitivity in PCa patients (Fig. 3E and Supplementary Fig. S4B). The gene discussed is CD9; the disease is posterior cortical atrophy.